Answers are grounded in this paper and cite their sources.
This post hoc analysis of PIONEER I and II randomized clinical trials assesses whether receiving adalimumab is associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.
No takes yet. Share an insight, caveat, or question.
Gunter et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: